Drugs targeted to inflammatory cytokines, adrenocorticotropic hormone receptor (ACTH), TLR4/NF-κB, and TGF-β1 receptors partly prevent the occurrence and development of diabetic nephropathy in clinical trials (Rao et al., 2019). The gene discussed is NFKB1; the disease is diabetic kidney disease.